Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amadiab
- Development stage
- Unknown
- Lead developer
- Lapi Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amadiab is an oral antidiabetic medication containing glimepiride, a second-generation sulfonylurea. Developed and marketed by PT. Lapi Laboratories in Indonesia, it is indicated for the management of type 2 diabetes mellitus in patients whose hyperglycemia cannot be controlled by diet and exercise alone. The drug works by binding to the sulfonylurea receptor 1 (SUR1) subunit of ATP-sensitive potassium channels on the surface of pancreatic beta cells. This binding induces channel closure, leading to cell depolarization, calcium influx, and subsequent insulin secretion. Amadiab is available in tablet form in strengths of 1 mg, 2 mg, 3 mg, and 4 mg, and can be used as monotherapy or in combination with other antidiabetic agents like metformin or insulin.
- Brand names
- Amadiab
- Other names
- glimepiride
02
Targets
SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on Amadiab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amadiab.